{
  "documentMetadata": {
    "title": "Jugular Vein Suppurative (Septic) Thrombophlebitis, Lemierre's syndrome",
    "sourceFile": "Jugular Vein Suppurative (Septic) Thrombophlebitis, Lemierre's syndrome.pdf",
    "lastUpdated": "2025-01-06"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Suppurative thrombophlebitis of the internal jugular vein is commonly referred to as Lemierre, or Lemierre's syndrome, when:",
        "The syndrome develops after, or during, an acute pharyngeal infection (viral or bacterial) in healthy young adults and",
        "Accompanied by positive blood cultures for Fusobacterium necrophorum",
        "Maybe complicated by pulmonary septic emboli and/or hematogenous seeding of other sites: e.g., septic arthritis, osteomyelitis, liver abscess, brain abscess",
        "Other, less common, bacterial etiologies listed below",
        "Excellent reviews: J Microbiol Immunol Infection 2020;53: 513 and Cureus. 2023;15:e43685"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Fusobacterium necrophorum (most common) and other Fusobacterium species.",
        "Various Enterobacterales",
        "Other anaerobic bacteria: Eikenella corrodens, Porphyromonas sp, Bacteroides species",
        "Streptococcus pyogenes and Streptococcus anginosus group",
        "Rarely Staphylococcus aureus to include MRSA"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy focuses on possible F. necrophorum; specific therapy tailored to the identified organism",
        "Treatment is a combination of surgical drainage/debridement and antimicrobial therapy",
        "F. necrophorum is resistant to penicillin G due to production of penicillinase"
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Suggested empiric therapy:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Metronidazole",
                "dose": "500 mg",
                "route": "IV/po",
                "frequency": "q8h",
                "connector": "+"
              },
              {
                "drug": "Ceftriaxone",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "once daily"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV (over 4 hr)",
            "frequency": "q8h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Imipenem-cilastatin",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q6h",
            "connector": "or"
          },
          {
            "drug": "another carbapenem"
          }
        ]
      }
    },
    {
      "type": "list",
      "items": [
        "Can potentially narrow therapy based on culture results. NOTE: in vitro susceptibility of F. necrophorum is not routinely available",
        "If the suppuration is due to an infected IV internal jugular line, and not a complication of pharyngitis, start empiric treatment for MRSA with Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see Vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Clindamycin",
            "dose": "600-900 mg",
            "route": "IV",
            "frequency": "q8h"
          }
        ],
        "notes": "is active vs F. necrophorum"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Due to location and/or necrosis, treatment duration often continues for 3-6 weeks.",
        "Avoid macrolides and fluoroquinolones as Fusobacteria are resistant."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "F. necrophorum produces beta-lactamases; hence, recommendation for Piperacillin-tazobactam",
        "Also, activity of antibacterial regimen should include oral streptococci"
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Other References:"
        },
        {
          "type": "list",
          "items": [
            "J Microbiol Immunol Infect 2020;53: 513 and Cureus. 2023;15:e43685",
            "Original report by Lemierre: Lancet 1936; 227:701"
          ]
        }
      ]
    }
  ]
}